Project Grant R35GM164205
- The National Institute of General Medical Sciences awarded the University of Texas Health Science Center at Houston $429,000 on March 6, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the regulation of ER-phagy during cellular stresses. The research comprises two programs. Program 1 examines the ER-phagy receptor TEX264, focusing on its interaction with P62, an autophagy receptor for ubiquitinated cargos, and how this interaction facilitates...
- The National Institute of General Medical Sciences awarded the University of Texas Health Science Center at Houston $390,000 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate inter-organelle unfolded protein response coordination and cellular proteostasis. The research explores how eukaryotic cells coordinate organelle-specific unfolded protein responses across mitochondria, the endoplasmic reticulum, and the cytosol to maintain...
- The National Institute of General Medical Sciences awarded Texas A&M University System Health Science Center $420,657 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, assistance type Project Grant) to support research on nanoscale structure and dynamics within nuclear pores and condensates. The funded research examines intrinsically disordered proteins and regions in the proteome, with focus on transport properties of the nuclear pore complex and...
- The National Institute of General Medical Sciences, part of the National Institutes of Health within the Department of Health and Human Services, awarded The University of Texas Southwestern Medical Center $488,525 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859), a Project Grant (R35GM162011). The award funds evolution-guided studies of mitochondrial activities and the host response to infectious agents. The research characterizes newly identified...
- This $868,584 Project Grant, awarded September 1, 2025, by the National Institute of General Medical Sciences through its Biomedical Research and Research Training program (CFDA 93.859), supports fundamental research investigating how ribonucleic acid (RNA) modifications regulate adaptive messenger RNA (mRNA) translation. The University of Texas Health Science Center at Houston will conduct a two-year research initiative (through August 31, 2027) focused on elucidating the roles of TRMT1L, a...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded Texas Tech University Health Sciences Center $575,904 on September 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate protein-based transgenerational inheritance in mammals. The funded research examines how paternal environmental exposures transmit phenotypic changes to offspring across generations, with focus on establishing germ granules consisting of...
- The National Institute of General Medical Sciences awarded Texas A&M University System Health Science Center $418,952 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop light-controlled tools and genetically encoded sensors for studying calcium signaling at membrane contact sites in living cells. The research program integrates three directions. First, the team will engineer light-activated actuators to control organelle positioning and...
- The National Institute of General Medical Sciences awarded the University of Texas Health Science Center at Houston $423,576 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop machine learning-driven computational tools for interpreting electron cryo-microscopy and electron cryo-tomography data of complex biological assemblies. The project addresses significant gaps in current cryo-EM modeling software by building a unified framework to model...
- The National Institute of General Medical Sciences awarded $420,476 to the University of Texas Health Science Center at Houston on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support structural and mechanistic studies of eukaryotic gene transcription regulation. The recipient will conduct five years of integrated structural and molecular biology research investigating how the human CDK8 kinase module (comprising MED13, MED12, CDK8, and CYCC)...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded The University of Texas Southwestern Medical Center $449,900 on May 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop new methods for detecting protein phosphorylation in cells. The project will exploit a novel bacterial effector protein, Legionella pneumophila LnaB, which attaches adenosine monophosphate...
The National Institute of General Medical Sciences, part of the National Institutes of Health within the Department of Health and Human Services, awarded Texas Tech University Health Sciences Center $492,625 under CFDA 93.859 (Biomedical Research and Research Training) on September 1, 2026, to support research on quality control pathways governing protein translocation and folding in the endoplasmic reticulum. The research focuses on understanding molecular mechanisms regulating protein movement through the SEC61 translocon, a cellular channel critical for the biogenesis of secretory and membrane proteins comprising approximately 30 percent of the human proteome. The investigator previously identified a complex linking the ER stress sensor IRE1A, the SEC61 translocon, and its partner protein SEC63, and demonstrated that SEC63 inhibits IRE1A by promoting chaperone recruitment. Under this project grant, work will define how the SEC61/SEC63 complex regulates IRE1A signaling during ER stress, including structural analysis of recombinant IRE1A/SEC61/SEC63 complexes using cryo-electron microscopy and investigation of how this complex protects pancreatic beta cells from ER stress-induced apoptosis. The research will also examine how SEC63 alleviates translocation pauses by promoting chaperone binding to nascent chains, coupling efficient translocation with proper protein folding. Performance is based in Lubbock, Texas. The award period runs from September 1, 2026, through May 31, 2031. The assistance type is Project Grant.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $492.6k | 8/21/26 |